JP2016505534A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505534A5
JP2016505534A5 JP2015543399A JP2015543399A JP2016505534A5 JP 2016505534 A5 JP2016505534 A5 JP 2016505534A5 JP 2015543399 A JP2015543399 A JP 2015543399A JP 2015543399 A JP2015543399 A JP 2015543399A JP 2016505534 A5 JP2016505534 A5 JP 2016505534A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015543399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505534A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/074012 external-priority patent/WO2014079787A1/en
Publication of JP2016505534A publication Critical patent/JP2016505534A/ja
Publication of JP2016505534A5 publication Critical patent/JP2016505534A5/ja
Pending legal-status Critical Current

Links

JP2015543399A 2012-11-20 2013-11-18 置換1,6−ナフチリジン Pending JP2016505534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12193311 2012-11-20
EP12193311.3 2012-11-20
PCT/EP2013/074012 WO2014079787A1 (en) 2012-11-20 2013-11-18 Substituted 1,6-naphthyridines

Publications (2)

Publication Number Publication Date
JP2016505534A JP2016505534A (ja) 2016-02-25
JP2016505534A5 true JP2016505534A5 (enExample) 2017-01-05

Family

ID=47189816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543399A Pending JP2016505534A (ja) 2012-11-20 2013-11-18 置換1,6−ナフチリジン

Country Status (13)

Country Link
US (1) US9657014B2 (enExample)
EP (1) EP2922540A1 (enExample)
JP (1) JP2016505534A (enExample)
KR (1) KR20150085538A (enExample)
CN (1) CN104812387A (enExample)
AR (1) AR093519A1 (enExample)
BR (1) BR112015011094A2 (enExample)
CA (1) CA2890685A1 (enExample)
HK (1) HK1207317A1 (enExample)
MX (1) MX2015006364A (enExample)
RU (1) RU2015120217A (enExample)
TW (1) TW201425312A (enExample)
WO (1) WO2014079787A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI529171B (zh) 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-萘啶衍生物
US20160016951A1 (en) * 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
EA201791781A1 (ru) * 2015-02-11 2018-02-28 Базилеа Фармацойтика Интернациональ Аг Производные замещенного моно- и полиазанафталина и их применение
SG11201706869XA (en) 2015-03-24 2017-09-28 Shanghai Yingli Pharm Co Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
WO2017079641A1 (en) * 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
EA039638B1 (ru) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Антагонисты мускаринового рецептора 4 и способы их применения
JPWO2018159805A1 (ja) 2017-03-03 2020-01-09 国立大学法人京都大学 膵前駆細胞の製造方法
BR112021012950A2 (pt) 2019-01-03 2021-09-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Métodos e materiais para aumentar os níveis de polipeptídeo do fator de transcrição eb
TW202134231A (zh) 2019-12-06 2021-09-16 美商紐羅克里生物科學有限公司 蕈毒受體4拮抗劑及使用方法
WO2022133303A1 (en) * 2020-12-18 2022-06-23 The Scripps Research Institute Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
WO2025252732A1 (en) * 2024-06-04 2025-12-11 Syngenta Crop Protection Ag Nitrogen-containing 6-membered bicyclic derivatives with microbiocidal activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605437D0 (en) 1996-03-15 1996-05-15 Iaf Biochem Int Cytomegalovirus inhibiting compounds
AU740745B2 (en) * 1997-12-11 2001-11-15 Biochem Pharma Inc. Antiviral compounds
AU2002218902A1 (en) 2000-12-27 2002-07-08 Shire Biochem Inc. Macrocyclic anti-viral compounds
WO2006017672A2 (en) * 2004-08-03 2006-02-16 Serenex Inc. 2, 8-disubstituted naphthyridine derivatives
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
EP2380878B1 (en) 2009-01-19 2013-08-14 Daiichi Sankyo Company, Limited Cyclic compound having hetero atom
KR20110128908A (ko) * 2009-03-02 2011-11-30 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 8-치환된 퀴놀린 및 관련 유사체
NZ596154A (en) 2009-04-06 2013-12-20 Daiichi Sankyo Co Ltd Cyclic compound having substituted phenyl group
JP6126528B2 (ja) 2010-07-07 2017-05-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System 神経新生促進化合物
JP2012036168A (ja) 2010-07-15 2012-02-23 Daiichi Sankyo Co Ltd ヘテロ原子を有する環状化合物を含有する医薬組成物

Similar Documents

Publication Publication Date Title
JP2014026276A5 (enExample)
JP2014026274A5 (enExample)
JP2014026275A5 (enExample)
JP2015511482A5 (enExample)
JP2015508051A5 (enExample)
JP2013212124A5 (enExample)
JP2015509368A5 (enExample)
JP2014189812A5 (enExample)
JP2016501900A5 (enExample)
JP2013241444A5 (enExample)
JP2014503786A5 (enExample)
JP2014156601A5 (enExample)
JP2015107586A5 (enExample)
JP2015500269A5 (enExample)
JP2014220238A5 (enExample)
JP2015077594A5 (enExample)
JP2016505534A5 (enExample)
JP2016526891A5 (enExample)
JP2014520787A5 (enExample)
JP2015518513A5 (enExample)
JP2014531903A5 (enExample)
JP2014520786A5 (enExample)
JP2014534151A5 (enExample)
JP2014205658A5 (enExample)
JP2017509782A5 (enExample)